NMRD - Nemaura Medical Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.5500
-0.0800 (-4.91%)
At close: 4:00PM EST

1.54 -0.01 (-0.65%)
After hours: 4:00PM EST

Stock chart is not supported by your current browser
Previous Close1.6300
Open1.6400
Bid1.04 x 1000
Ask2.15 x 800
Day's Range1.5000 - 1.6400
52 Week Range1.5000 - 6.8000
Volume58,590
Avg. Volume161,153
Market Cap317.88M
Beta (3Y Monthly)-0.14
PE Ratio (TTM)N/A
EPS (TTM)-0.02
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire8 days ago

    Nemaura Successfully Completes Clinical Studies for SugarBEAT® FDA De-Novo 510(k) Submission

    Nemaura Medical Inc. (NMRD), a medical technology company developing sugarBEAT® as a non-invasive affordable and flexible Continuous Glucose Monitor (CGM) for use by people with diabetes and pre-diabetics, today reported that it has successfully completed the clinical studies needed to support a De-Novo 510(k) submission to the U.S. Food & Drug Administration (“FDA”) for approval of its sugarBEAT® product. The global addressable market for CGM is estimated at $82B per annum, with the U.S. market estimated at $13.5B.

  • GlobeNewswire22 days ago

    Nemaura Signs License and Distribution Agreement for SugarBEAT® Commercial Launch in Qatar

    LOUGHBOROUGH, England. Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose.

  • GlobeNewswire28 days ago

    Nemaura Medical to Present at the Canaccord Genuity Medical Technologies & Diagnostics Forum

    Nemaura Medical Inc. (NMRD), a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible continuous glucose monitor (CGM) for use by people with diabetes and pre-diabetics, today announced that Chief Business Officer, Bashir Timol, will be presenting at the Canaccord Genuity Medical Technologies & Diagnostics Forum on Thursday, November 15, 2018 in New York.

  • GlobeNewswirelast month

    Nemaura Medical to Present at the Stifel 2018 Healthcare Conference

    Nemaura Medical Inc. (NMRD), a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible continuous glucose monitor (CGM) for use by people with diabetes and pre-diabetics, today announced that Chief Business Officer, Bashir Timol, will be presenting at the Stifel 2018 Healthcare Conference on Tuesday, November 13, 2018 in New York.

  • GlobeNewswirelast month

    Nemaura Medical Inc. Reports Second Quarter 2018 Financial Results

    Nemaura Medical Inc. (NMRD), a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible continuous glucose monitor (CGM) for use by people with diabetes and pre-diabetics recently reported financial results for the second quarter ended September 30, 2018. Dr. Faz Chowdhury, CEO of Nemaura Medical commented “we have maintained our well capitalised financial position to better support the expected commercial launch of sugarBEAT® in the United Kingdom in the coming weeks.

  • GlobeNewswirelast month

    Nemaura Successfully Develops Predictive Algorithms and Alarm Functionality for Continuous Glucose Monitor SugarBEAT®

    LOUGHBOROUGH, England. Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing sugarBEAT® as a non-invasive affordable and flexible Continuous Glucose.

  • GlobeNewswire2 months ago

    Nemaura to Host Investor Webinar on October 23rd 2018 to Provide Update on Recent Developments

    LOUGHBOROUGH, England - Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing sugarBEAT® as a non-invasive affordable and flexible Continuous Glucose.

  • GlobeNewswire3 months ago

    Nemaura Reports Positive Zero Finger-Stick Calibration Data for SugarBEAT® Continuous Glucose Monitor

    Nemaura Medical Inc. (NMRD), a medical technology company developing sugarBEAT® as a non-invasive affordable and flexible Continuous Glucose Monitor (CGM) for use by people with diabetes and pre-diabetics, today announced data indicating sugarBEAT® could potentially be used as an adjunctive CGM without the need for finger-stick calibration. 66% of patches worn by 92% of the patients generating 9,863 paired data points were evaluated, with 58% of these paired data points giving a MARD of 13.61%.

  • GlobeNewswire3 months ago

    Nemaura Signs Letter of Intent for SugarBEAT® Commercial Launch in Qatar

    Nemaura Medical Inc., a medical technology company developing sugarBEAT ® as a non-invasive affordable and flexible Continuous Glucose Monitor for use by persons with diabetes and pre-diabetics, today ...

  • Why Micro Cap Nemaura Medical Skyrocketed 32% Yesterday
    Motley Fool3 months ago

    Why Micro Cap Nemaura Medical Skyrocketed 32% Yesterday

    The clinical-stage upstart is making progress in advancing a new type of glucose monitor to market.

  • Business Wire5 months ago

    Nemaura Places SugarBEAT® Manufacturer Order for UK Commercial Launch

    Nemaura Medical Inc. (NMRD), a medical technology company developing the wireless sugarBEAT® non-invasive glucose monitoring system for adjunctive use by persons with diabetes, today announced it has placed an initial order with its designated UK-based contract manufacturer for 12,500 sugarBEAT® rechargeable transmitters, which will be supplemented with approximately 100,000 skin-patches per month, also manufactured in the UK, in preparation for the anticipated sugarBEAT® product launch in the coming months. SugarBEAT® consists of a daily-disposable adhesive skin-patch connected to a rechargeable transmitter, with an app displaying glucose readings at five minute intervals, and is expected to launch initially in the United Kingdom, upon CE Mark approval.

  • Business Wire6 months ago

    Nemaura Medical Inc. Reports Full Year Financial Results

    Nemaura Medical Inc. (NMRD), a medical technology company developing the wireless sugarBEAT® non-invasive glucose monitoring system for adjunctive use by persons with diabetes, today announced financial results for the fiscal year ended March 31, 2018. Entered into a definitive collaboration agreement with Dallas Burston Ethitronix (DBE) to commercialize sugarBEAT® in the European Economic Area (EEA).

  • Business Wire6 months ago

    Nemaura Medical Signs Joint Collaboration Agreement for European Commercialization

    Nemaura Medical Inc. (NMRD), a medical technology company developing the wireless sugarBEAT® non-invasive glucose monitoring system for adjunctive use by persons with diabetes, today announced that it has entered in to a definitive joint Collaboration Agreement with Dallas Burston Ethitronix (DBE) to commercialize sugarBEAT® in the European Economic Area (EEA). “We are pleased to extend our relationship with DBE and believe their expertise will play an important role in the commercialization of sugarBEAT®.” said Dr. Faz Chowdhury, Chairman and CEO of Nemaura. DBE was founded by Dr. Dallas Burston (MBBS), a pharmaceutical marketing entrepreneur specializing in selling breakthrough medical products into European markets.

  • Business Wire7 months ago

    Nemaura Medical to Present at the UBS Global Healthcare Conference

    Nemaura Medical Inc. (NMRD), a medical technology company developing the wireless sugarBEAT® non-invasive glucose monitoring system for adjunctive use by persons with diabetes, today announced that Chief Business Officer, Bashir Timol, will be presenting at the UBS Global Healthcare Conference, being held May 21-23, 2018 in New York. Nemaura Medical Inc. (NMRD), is a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible glucose monitoring system for adjunctive use by persons with diabetes.

  • Business Wire8 months ago

    Nemaura Medical Appoints Bashir Timol Chief Business Officer

    Nemaura Medical Inc. , a medical technology company developing the wireless sugarBEAT® non-invasive glucose monitoring system for adjunctive use by persons with diabetes, today announced that Bashir Timol, current Director of Strategy & Corporate Development, has been named Chief Business Officer, effective immediately.

  • Business Wire8 months ago

    Nemaura Medical Appoints The Ruth Group as Investor and Public Relations Counsel

    Nemaura Medical Inc. , a medical technology company developing the wireless sugarBEAT® non-invasive glucose monitoring system for adjunctive use by persons with diabetes, today announced that it has appointed The Ruth Group , a leading healthcare-focused strategic communications firm, to lead its investor and public relations initiatives in the United States and help build awareness of the Company’s ...

  • Business Wire9 months ago

    Nemaura Medical to Ring the Nasdaq Closing Bell

    Nemaura Medical Inc. , a medical technology company developing the wireless sugarBEAT® non-invasive glucose monitoring system for adjunctive use by persons with diabetes, today announced that Bashir Timol, Director of Strategy and Corporate Development, will ring the closing bell of the Nasdaq Stock Market on Tuesday, March 6, 2018 at 4:00 pm ET.

  • Business Wire9 months ago

    Nemaura Announces Expansion of Manufacturing Capabilities for SugarBEAT® Commercial Launch

    Nemaura Medical Inc. , a medical technology company developing the wireless sugarBEAT® non-invasive glucose monitoring system for adjunctive use by persons with diabetes, today announced it has commenced expansion into new manufacturing facilities, enabling large scale production of its proprietary sensor technology.

  • Business Wire10 months ago

    Nemaura Medical Inc. Reports Third Quarter 2017 Financial Results

    Nemaura Medical Inc. , a medical technology company developing the wireless sugarBEAT® non-invasive glucose monitoring system for adjunctive use by persons with diabetes today reported financial results for the third quarter ended December 31, 2017.

  • Business Wire10 months ago

    Nemaura Announces Positive Results for its SugarBEAT® European Clinical Program

    Nemaura Medical Inc. , a medical technology company developing the wireless sugarBEAT® non-invasive glucose monitoring system for adjunctive use by persons with diabetes today announced positive summary data for its sugarBEAT® European clinical trial program.